Publication date: Jun 26, 2025

For example, the PRAME-targeted TCR-T cell therapy IMA203 has shown early response rates near 50% in HLA-A*02:01positive patients, although applicability is limited by HLA restriction, he noted. They can also help simplify treatment logistics through eliminating the need for high-dose interleukin-2, for example, Johnson explained. Emerging T-cell receptor T-cell (TCR-T) therapies represent another novel approach, Johnson continued. Tumor-infiltrating lymphocyte (TIL) therapy, such as lifileucel (Amtagvi), the first FDA-approved TIL product, has demonstrated response rates between 30% to 50% in this setting. “[In melanoma], we’re still seeing a 10% to 30% response rate in the frontline setting. In response, the field is increasingly focused on cellular therapy approaches for immunotherapy-refractory disease, Johnson reported. We’ve come a long way, but [still have] a long way to go. Unlike TILs, these therapies can be derived from peripheral blood, reducing the need for surgical tumor resection.

Semantics